COVID-19 or treatment associated immunosuppression may trigger hepatitis B virus reactivation: A case report.
World J Clin Cases
; 9(19): 5266-5269, 2021 Jul 06.
Article
em En
| MEDLINE
| ID: mdl-34307577
ABSTRACT
BACKGROUND:
Since the initial recognition of coronavirus disease 2019 (COVID-19) in Wuhan, this infectious disease has spread to most areas of the world. The pathogenesis of COVID-19 is yet unclear. Hepatitis B virus (HBV) reactivation occurring in COVID-19 patients has not yet been reported. CASESUMMARY:
A 45-year-old hepatitis B man with long-term use of adefovir dipivoxil and entecavir for antiviral therapy had HBV reactivation after being treated with methylprednisolone for COVID-19 for 6 d.CONCLUSION:
COVID-19 or treatment associated immunosuppression may trigger HBV reactivation.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Risk_factors_studies
Idioma:
En
Revista:
World J Clin Cases
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
China